Y. Mitani

发表

[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].

Y. Shitaka, Y. Mitani, A. Nagakura, 2010, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Mechanism of synergism between antimicrobial peptides magainin 2 and PGLa.

M. Zasloff, K. Miyajima, K. Matsuzaki, 1998, Biochemistry.

Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for γ-secretase modulators with oral efficacy against cognitive deficits in Alzheimer's disease model mice.

Y. Mitani, H. Akashiba, J. Yarimizu, 2020, Bioorganic & medicinal chemistry.

Discovery of N-ethylpyridine-2-carboxamide derivatives as a novel scaffold for orally active γ-secretase modulators.

Takayuki Suzuki, Y. Mitani, H. Akashiba, 2019, Bioorganic & medicinal chemistry.

Discovery of novel scaffolds for γ-secretase modulators without an arylimidazole moiety.

Y. Mitani, Hideyoshi Fuji, H. Akashiba, 2018, Bioorganic & medicinal chemistry.

Heterodimer formation between the antimicrobial peptides magainin 2 and PGLa in lipid bilayers: a cross-linking study.

T. Tachi, T. Hara, H. Kodama, 2001, Biochemistry.

Strategy for structural elucidation of drugs and drug metabolites using (MS)n fragmentation in an electrospray ion trap.

Y. Mitani, S. Terashita, T. Shiraga, 2003, Journal of mass spectrometry : JMS.

Strategy for structure elucidation of drug metabolites derived from protonated molecules and (MS)n fragmentation of zotepine, tiaramide and their metabolites.

Y. Mitani, T. Shiraga, Z. Tozuka, 2002, Drug metabolism and pharmacokinetics.

Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice

Y. Shitaka, Y. Mitani, N. Matsuoka, 2012, The Journal of Neuroscience.

Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.

Y. Mitani, Y. Tokuma, T. Shiraga, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in Models of Parkinson's Disease and Cognition

A. Iwashita, Hiroko Yamamoto, T. Mihara, 2007, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates

Makoto Asai, M. Asai, Keni Ni, 2014, Neuropharmacology.

Amelioration of cognitive deficits in plaque‐bearing Alzheimer's disease model mice through selective reduction of nascent soluble A β 42 without affecting other A β pools

Y. Shitaka, Y. Mitani, N. Matsuoka, 2013, Journal of neurochemistry.